Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Xolair review continues

Executive Summary

"For the time being the review of E25 dossier in U.S. and in Europe is ongoing," Novartis Global Pharma Development Head Jorg Reinhardt said during the company's Oct. 11 teleconference. "The Pink Sheet" (Oct. 16, p. 14) incorrectly quoted Novartis as saying the review of the allergy/asthma monoclonal antibody therapy is on hold. Clinical trials of omalizumab are on hold after toxicity findings related to Xolair and a similar agent, E26 (1"The Pink Sheet" Sept. 18, In Brief)

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts